clinical trial · NCT04848506
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Cytokinetics·phase3·enrolling by invitation·n = 900
Symptomatic Hypertrophic Cardiomyopathy (HCM)Aficamten (5 - 20 mg)
brief summary
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
started
May 6, 2021
primary completion
Mar 1, 2028
completion
Mar 1, 2028
last updated
Jan 22, 2026
official title
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol